Scientists at the Universities of Aberdeen and Dundee have established a foot in the door in finding new, precision treatments for patients with oesophageal cancer, one of the hardest forms of the disease to treat.
Jun 15, 2017
0
2
The targeted therapy gefitinib appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. In a phase III clinical trial, patients with epidermal growth factor receptor ...
May 18, 2017
0
5
Women with ectopic pregnancies could be spared surgery if they are treated with a lung cancer drug, a study suggests.
Sep 9, 2013
0
0
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival—up to two years—among patients prescribed two of the most widely used drugs in a class of anticancer ...
Sep 5, 2013
0
0
Significant advances have taken place in the management of patients with advanced and metastatic non–small-cell lung cancer (NSCLC) over the last 5 years. Traditionally, all advanced NSCLC patients were treated in a similar ...
Jul 25, 2013
0
0
The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung ...
Apr 22, 2013
0
0
(Medical Xpress)—For many patients with non-small-cell lung carcinoma (NSCLC), tumorigenesis is fueled by mutations that hyperactivate the epidermal growth factor receptor (EGFR) signaling protein. These individuals may ...
Feb 15, 2013
0
0
Adding lung cancer drugs to targeted melanoma treatment could increase survival for certain patients, according to research published in Cancer Discovery today.
Feb 12, 2013
0
0
New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Sep 29, 2012
0
0
A team of neuroscientists and chemists from the U.S. and China today publish research suggesting that a class of currently used anti-cancer drugs as well as several previously untested synthetic compounds show effectiveness ...
Sep 24, 2012
0
0
Gefitinib INN ( /ɡɛˈfɪtɨnɪb/), trade name Iressa, is a drug used in the treatment of certain types of cancer, particularly those with mutated and overactive EGFR. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. It is marketed by AstraZeneca and Teva.
This text uses material from Wikipedia, licensed under CC BY-SA
